Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 3;13(1):50–57. doi: 10.1093/ecco-jcc/jjy125

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Kaplan–Meier analyses for [A] time to sustained resolution of baseline arthritis/arthralgia in CD [GEMINI 2], [B and C] time to occurrence of new arthritis/arthralgia in CD [GEMINI 2 and 3 respectively], [D] time to new/worsening arthritis/arthralgia in CD [GEMINI 2], and [E] time to new/worsening of arthritis/arthralgia in UC [GEMINI 1]. In GEMINI 1 and 2, the VDZ group includes both induction responders and non-responders, the VDZ/PLA group is responders only, and the PLA group is both responders and non-responders. CD, Crohn’s disease; PLA, placebo; VDZ, vedolizumab; UC, ulcerative colitis.